Ashland adds high purity sucrose and parenteral applications to injectables portfolio, and highlights expanded low nitrite pharmaceutical excipients

Ashland showed multiple new and optimized pharmaceutical product offerings during CPHI Frankfurt and AAPS PharmSci 360.

To respond to global customer needs, Ashland has introduced vialose™ sucrose, a high purity sucrose for parenteral formulations that protects and shields biological molecules in injectables. Vialose™ sucrose meets the lowest levels of endotoxins (<0.2 g/EU) and meets NF, EP, JP, BP and ChP monograph specifications. The addition of sucrose expands Ashland’s portfolio of vialose™ high purity sugar excipients, which already includes trehalose dihydrate. These sugars are used in life saving medicines as lyoprotectants and for protein stabilization in monoclonal antibodies, antibody-drug conjugates (ADCs), vaccines, peptides and stem cells. This growing family of stabilizing sugars demonstrates Ashland’s commitment to delivering high-quality ingredients for the injectable and vaccine markets. Looking ahead, Ashland is planning to bring vialose™ mannitol to market later in 2026, further broadening its offerings to meet diverse formulation needs.

“We’re excited to introduce vialose™ sucrose, our latest premier performance sugar for use in biologic medicines,” said Shawn Branning, global business line owner – cyclodextrins and biopharma, Ashland. “Our high purity sucrose, used to stabilize proteins and act as a lyoprotectant, is tested to meet the lowest levels of endotoxins and ChP monograph specifications, making it an ideal choice for use in biologic formulations.”

Within the pharmaceuticals portfolio, Ashland offers an array of oral solid dose (OSD) solutions, parenteral excipients (injectables) and film coating system solutions that improve, protect, and moderate the delivery of medicines. These ingredients include both time-controlled and immediate-release agents, as well as high-purity and low-nitrite offerings.

To reduce the risk of nitrosamines in drug products, Ashland offers excipients with competitively low nitrite levels to help mitigate associated risks and ensure patient safety. By providing detailed nitrite specifications, Ashland empowers customers to make informed decisions and enhance their own quality control measures. Plasdone™ low nitrite povidone and polyplasdone™ LN crospovidone grades offer a nitrite specification of <100ppb with results reported on every CoA, setting a new benchmark for transparency and regulatory compliance. Benecel™ xr/xrf low nitrite hypromellose offers a nitrite specification of <200ppb with results reported on every CoA.

Ashland solvers are known as the expert’s expert, helping customers solve tomorrow’s challenges today. The company has R&D centers of excellence in every region around the globe. Their iSolve℠ digital portal puts information at users’ fingertips. Ashland has regulatory experts that support customers across all regions and in-house manufacturing, backward integration, sourcing, and delivery in 93 countries and is responsibly solving for healthier lives, everywhere.

“Our newly introduced excipients with signiffcantly reduced nitrite levels—including plasdone™ low nitrite povidone, polyplasdone™ LN crospovidone and benecel™ low nitrite hypromellose—help our customers mitigate nitrosamine formation in their final drug products. Providing high-quality materials that equip our stakeholders to make informed decisions, coupled with superior customer and technical service continues to position Ashland as an industry leader in the pharmaceutical space,”

Caroline Cooreman, director strategy and business development, OSD, Ashland.

To learn more or to request a meeting at the tradeshows, visit the CPHI overview or the AAPS overview. For more information on vialose™ sucrose, viatel™ bioresorbable polymers, plasdone™ low nitrite povidone and polyplasdone™ LN crospovidone grades contact your local Ashland solver.

Download the full press release here Ashland adds high purity sucrose and parenteral applications to injectables portfolio, and highlights expanded low nitrite pharmaceutical excipients

or continue reading here

Source: Press release Ashland, Ashland adds high purity sucrose and parenteral applications to injectables portfolio, and highlights expanded low nitrite pharmaceutical excipients

If you have any questions or need a sample by Ashland, please feel free to contact us: